Proton beam therapy for lung metastasis of colorectal cancer
A Phase II Study of Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer
NA · National Cancer Center, Korea · NCT03566355
This study tests if proton beam therapy can help patients with lung cancer that has spread from colorectal cancer feel better when surgery isn't an option.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 36 (estimated) |
| Sex | All |
| Sponsor | National Cancer Center, Korea (other gov) |
| Locations | 1 site (Goyang-si, Gyeonggi-do) |
| Trial ID | NCT03566355 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of curative proton beam therapy specifically for patients with lung metastasis from colorectal cancer, diagnosed as adenocarcinoma. Participants will receive proton therapy five times a week, totaling 7200 cGy delivered over 15 fractions within three weeks. The study aims to determine if this targeted treatment can improve outcomes for patients who are not suitable for surgery due to various health conditions. It is a prospective, single-organ trial focusing on a specific patient population.
Who should consider this trial
Good fit: Ideal candidates are patients with histologically confirmed colon adenocarcinoma and limited lung metastasis who are not suitable for surgery.
Not a fit: Patients with other types of cancer, extensive metastasis, or those who have had recent invasive cancer diagnoses may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a non-invasive curative option for patients with lung metastasis from colorectal cancer.
How similar studies have performed: While proton therapy is a well-established treatment modality, this specific application for lung metastasis of colorectal cancer is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically diagnosed colon adenocarcinoma in primary or metastatic lesions.. 2. If there is no other remote metastasis other than lung, or if there is, control is possible 3. If there are less than 2 lung metastatic lesions 4. If they refuse lung surgery or surgery is inappropriate (medically unsuitable for surgery due to surgery refusal, diabetes mellitus, high blood pressure, pulmonary disease, heart disease, etc., repeated surgery, poor systematic function, short disease-free period, etc.) Exclusion Criteria: 1. Other histologic cancer other than adenocarcinoma of the colorectal 2. Colorectal cancer without primary lesion resection 3. If there is another remote metastasis and is not completely resected or regulated 4. If the patient has experience of other invasive cancer diagnosis within 5 years of colorectal cancer diagnosis 5. Pregnancy and women under lactation
Where this trial is running
Goyang-si, Gyeonggi-do
- National Cancer Center Korea — Goyang-si, Gyeonggi-do, Korea, Republic of (RECRUITING)
Study contacts
- Principal investigator: Dae Yong Kim, M.D. — National Cancer Center Korea(South Korea)
- Study coordinator: Dae Yong Kim, M.D.
- Email: radiopia@ncc.re.kr
- Phone: 82-31-920-1721
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Colorectal Cancer, Lung Metastasis, Curative Proton Beam Therapy